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Migraine is a paroxysmal disorder characterised by attacks
of headache eventually associated with nausea, vomiting,
photophobia, phonophobia, and malaise. A fast-growing,
new class of anti-migraine drugs has recently been intro-
duced for the treatment of migraine: the serotonin (5-HT)
1B/1D agonists. Since the introduction of the first represen-
tative, sumatriptan, in 1983, several new compounds of this
class have been or are about to be approved for clinical use.
The main pharmacokinetic characteristics of triptans are
reported in Table 1 [1]. All the triptans are effective in a high
proportion of patients with recurrent migraine attacks, but
from the clinical perspective consistency of response, sus-
tained response and good tolerability are the areas that may
better clinically distinguish among individual triptans [2].
Michel D. Ferrari, in a review on migraine in The Lancet in
1998, defined the “future” problem of choice among the
new triptans as the “triptans war” [3]. In fact, comparative
literature data are often hard to understand because of lack
of standardised measures of efficacy and safety for different
doses, different ways of administration and different times
from the administration [4]. Besides, few comparative stud-
ies have been carried out with triptans other than sumatrip-
tan, almost always taken as a reference (Fig. 1). Indirect
comparisons such as meta-analyses only serve as estimates
of relative efficacy or safety that cannot substitute the poten-
tial usefulness of direct comparative research on a wide pop-
ulation. Moreover, few long-term efficacy and safety studies
have been published [5].
Table 2 reports the main pharmacoepidemiological para-
meters that are needed to evaluate the efficacy and safety of
triptans [6, 7]. Compliance may be defined as the extent to
which a patient’s behaviour conforms to medical advice [8].
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Abstract Despite the pharmaco-
kinetic differences among triptans
and the variety of ways of adminis-
tration, the clinical differences in
every day use of these drugs lack in
an accepted decisional tree. In fact,
there are a number of comparative
trials showing conflicting results
with regard to efficacy, onset of
action, safety and recurrence inci-
dence. That means that the patient’s
preference probably is the main cri-
terion for choosing one triptan vs.
others. This point of view is proba-
bly correct considering also that the
main cause of therapy failure is non-
compliance. A good migraine care
strategy requires a balance in what
the patient views as satisfactory, a
reasonable compromise between
efficacy and tolerability, and a care-
ful follow-up. Improvement in com-
pliance should be the main and more
immediate goal for the treatment of
migraine attacks.
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factors that alter drug distribution or metabolism, such as
renal or hepatic insufficiency, congestive heart failure,
anaemia, and alcoholism [11]. It has also been suggested
that a patient who is receiving specific drugs or drugs of a
certain class may be prone to having an adverse effect; how-
ever, few studies on headache patients are available (Table
Table 1 Pharmacokinetics of oral triptans. (Modified from [1])
Triptan Tmax (h) Cmax (ng/ml) F (%) t1/2 AUC (mg/l h) Metabolism
Sumatriptan
50 mg 2 31 14 2 118 MAO
100 mg 1.5 54 14 2 158 MAO
Rizatiptan
5 mg 1.2 7.8 38 1.4 17.4 MAO-A
10 mg 1 19.8 40 2 50 MAO-A
Zolmitriptan
2.5 mg 2 3 46 2.6 17 P450/MAO-A
Naratriptan
2.5 mg 2 12.6 74 5.5 98 Renal/CYP450
5 mg 2 23.9 68 5.3 200 Renal/CYP450
10 mg 1.5 46.1 68 5.5 387 Renal/CYP450
Eletriptan
40 mg 1.8 82 50 5.3 670 CYP450
80 mg 1.4 246 50 6.3 1661 CYP450
Frovatriptan
2.5 mg 3 7 29.6 25.7 94 CYP450
40 mg 5 53.4 17.5 29.7 881 CYP450
Almotriptan
12.5 mg 2.5 3 49.5 3.1 80 CYP450/MAO-A
25 mg 1.46 103 69 3.19 558.5 CYP450/MAO-A
AUC, area under the curve; MAO, monoamine oxidase; Tmax, time to maximum concentration; Cmax, maximum blood concentration; F,
bioavailability
A primary reason for poor compliance among patients
receiving medications for headache is adverse effects, many
of which are dose related. One difficulty is that triptans
often causes adverse effects at therapeutic doses. Some risk
factors for adverse effects that have been proposed include
age [9], number of drugs the patient is receiving [10] and
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Fig. 1 Comparison of mean thera-
peutic gain (±SD) with different
triptans. Frova, frovatriptan;
Almo, almotriptan; Nara, nara-
triptan; Suma, sumatriptan; Riza,
rizatriptan; Zolmi, zolmitriptan,
Eli, elitriptan. (Modified from [1])
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3). Comparing effective dose sizes, triptans seem to differ in
their capacity to cause adverse effects without any relation-
ship between adverse effect frequencies and absolute dose
size, logD, or absolute dose-size lipophilicity index (ADLI
= absolute dose in mg/LogD). Moreover, because of the trip-
tans’ similar high affinity for the 5-HT1B/1D receptors,
adverse effects could be mediated through mechanisms that
are unrelated to the intrinsic efficacy at those receptors [12]. 
In clinical practice, the choice of a triptan depends on a
number of factors. First of all, it must be decided to use a
triptan instead of another non-specific painkiller medicine.
At the moment a stratified approach for migraine attack
therapy is preferred to optimise positive reinforcement due
to the efficacy of the therapy;  triptans are able to reduce
the number of non-responders to usual therapy [13]. In
clinical practice, the differences outlined (sometimes with
conflicting results) in comparative clinical trials are imme-
diately undetectable, so that the efficacy or safety of dif-
ferent triptans is in many case overlapping for the clini-
cian. In this situation the main point to consider in choos-
ing triptans seems to be the patient’s preference. In fact,
the difference in direct costs, in Italy, are almost negligi-
ble, and the difference in preference by patients can be
resumed as the following:
1. Rapidity in onset of action;
2. Consistency in repeated use;
3. Mode of administration;
4. Previous use;
5. Incidence of side effects;
6. Counselling of other patients.
Keeping in mind this point, we can identify the more
acceptable drug, optimise the compliance and hope to target
the maximum therapeutic effect. A well-informed patient is
the first step for a good therapeutic strategy.
In conclusion, the most frequent question is: Which is the
best triptan? The best answer to this question is that it is the
wrong question! In fact, a patient’s expression of treatment
reference is a valuable thing to know, not only for the indi-
vidual’s clinical management, but also at the population
level for epidemiological and economic reasons. In agree-
ment with Sheftell and Fox [14], we believe that a good
migraine care strategy requires a balance with what the
patient views as satisfactory, a reasonable compromise
between efficacy and tolerability, and a careful follow-up.
Table 2 Clinical efficacy and safety parameters necessary to com-
pare triptans
Efficacy parameters
Therapeutic gain = Response rate in treated
subjects/Response rate in control group
Relative benefit increase = Therapeutic gain/Response rate in
control group
Number needed to treat = 100/Therapeutic gain
Safety parameters
Absolute risk increase = Adverse effects (AEs) rate in treated
subjects/AEs rate in control group
Relative risk increase = Absolute risk increase/AEs rate in
control group 
Number needed to harm = 100/Absolute risk increase
Table 3 Comparison of adverse effects and recurrence with different triptans. Data refer to oral administration unless otherwise indicated
Drug All AE, % Chest symptoms, % Recurrence, %
Placebo 29–46 1–3 10–44
Sumatriptan
100 mg 58 5 34
50 mg 56 5 34
Rectal 2 0 22
6 mg SC 59 5 46
Naratriptan
5 mg 18 0.2–1.0 32
Zolmitriptan
2.5 mg 39 3 26
Rizatriptan
5 mg 39 2 38
10 mg 31–47 5 41
Almotriptan
12.5 mg 46 0.4–2.0 18
Elitriptan
40 mg NR 7 21
50 mg NR 7 32
SC, subcutaneous; AE, adverse events; NR, not reported
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